AI Terminal
MEDICLINIC INTERNATIONAL PLC
Remuneration Information • Aug 5, 2022
4946_dirs_2022-08-05_91ebfaeb-e4fa-498e-9636-89d0ce7c083d.html
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1314V
Mediclinic International plc
05 August 2022
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
('Mediclinic', the 'Company', or the 'Group')
5 August 2022
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out the details of awards over ordinary shares in Mediclinic ('Shares') granted to directors and other persons discharging managerial responsibilities ('PDMRs') on 5 August 2022 under the Company's short-term incentive scheme ('STI') and long-term incentive plan ('LTIP'), in accordance with the Remuneration Policy and share plan rules approved by shareholders at the annual general meeting of the Company held on 28 July 2022.
| Name | Director/ PDMR | Number of Shares awarded under the STI | Number of Shares awarded under the LTIP |
| Dr Carel Aron van der Merwe | Director | 74 718 | 237 716 |
| Petrus Jurgens Myburgh | Director | 47 488 | 148 319 |
| David John Hadley | PDMR | n/a | 58 369 |
| Gert Cornelis Hattingh | PDMR | n/a | 28 716 |
| Dr Dirk Cornelius le Roux | PDMR | n/a | 22 450 |
| Dr Daniel Liedtke | PDMR | n/a | 52 074 |
| Magnus Oetiker | PDMR | n/a | 51 945 |
| Koert Hendrik Stefanus Pretorius | PDMR | n/a | 30 055 |
| Dr René Toua | PDMR | n/a | 23 594 |
| Dr Tyson Bruno Welzel | PDMR | n/a | 40 608 |
| Greg van Wyk | PDMR | n/a | 27 270 |
The above awards were granted for nil consideration and are based on the closing price of a Share on 4 August 2022, which equates to £4.98 per Share.
1.
Details of PDMR / person closely associated with them
a)
Name
Dr Carel Aron van der Merwe
2.
Reason for the notification
a)
Position / status
Group Chief Executive Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.1
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 74 718 |
d)
Aggregated information
Aggregated volume
Price
74 718
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
4.2
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 237 716 |
d)
Aggregated information
Aggregated volume
Price
237 716
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Petrus Jurgens Myburgh
2.
Reason for the notification
a)
Position / status
Group Chief Financial Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.1
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 47 488 |
d)
Aggregated information
Aggregated volume
Price
47 488
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
4.2
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 148 319 |
d)
Aggregated information
Aggregated volume
Price
148 319
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
David John Hadley
2.
Reason for the notification
a)
Position / status
Chief Executive Officer - Mediclinic Middle East
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 58 369 |
d)
Aggregated information
Aggregated volume
Price
58 369
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Gert Cornelis Hattingh
2.
Reason for the notification
a)
Position / status
Group Chief Governance Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 28 716 |
d)
Aggregated information
Aggregated volume
Price
28 716
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Dr Dirk Cornelius le Roux
2.
Reason for the notification
a)
Position / status
Group Chief Information Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 22 450 |
d)
Aggregated information
Aggregated volume
Price
22 450
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Dr Daniel Liedtke
2.
Reason for the notification
a)
Position / status
Chief Executive Officer: Hirslanden
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 52 074 |
d)
Aggregated information
Aggregated volume
Price
52 074
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Magnus Oetiker
2.
Reason for the notification
a)
Position / status
Group Chief Strategy Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 51 945 |
d)
Aggregated information
Aggregated volume
Price
51 945
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Koert Hendrik Stefanus Pretorius
2.
Reason for the notification
a)
Position / status
Group Chief Operating Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 30 055 |
d)
Aggregated information
Aggregated volume
Price
30 055
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Dr René Toua
2.
Reason for the notification
a)
Position / status
Group Chief Clinical Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 23 594 |
d)
Aggregated information
Aggregated volume
Price
23 594
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Dr Tyson Bruno Welzel
2.
Reason for the notification
a)
Position / status
Group Chief Innovation Officer - Mediclinic International plc
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 40 608 |
d)
Aggregated information
Aggregated volume
Price
40 608
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
1.
Details of PDMR / person closely associated with them
a)
Name
Greg van Wyk
2.
Reason for the notification
a)
Position / status
Chief Executive Officer: Mediclinic Southern Africa
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mediclinic International plc
b)
LEI
2138002S5BSBIZTD5I60
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification Code
Ordinary Shares
GB00B8HX8Z88
b)
Nature of the transaction
Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £nil | 27 270 |
d)
Aggregated information
Aggregated volume
Price
27 270
£nil
e)
Date of the transaction
5 August 2022
f)
Place of the transaction
Outside a trading venue
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBDGDIXDGDGDU